New Treatment for Liver Cancer Using Electrochemotherapy
Author Information
Author(s): Luerken Lukas, Goetz Andrea, Mayr Vinzenz, Zhang Liang, Schlitt Alexandra, Haimerl Michael, Schlitt Hans-Jürgen, Grube Matthias, Kandulski Arne, Einspieler Ingo, Nagai Yoshinori
Primary Institution: University Hospital Regensburg
Hypothesis
Is CT-navigated stereotactic percutaneous electrochemotherapy (SpECT) a safe and effective treatment for primary and secondary liver malignancies?
Conclusion
SpECT appears to be a safe and effective new local treatment modality for primary and secondary liver malignancies.
Supporting Evidence
- 95.7% primary technique efficacy was achieved for the lesions treated.
- No local tumor progression was observed in the study.
- Minor complications occurred in 43.5% of procedures, but no major complications were reported.
- The mean follow-up time was 15 months, with a mean time to progression of 3.8 months for patients with recurrences.
Takeaway
Doctors are trying a new way to treat liver cancer using electricity and medicine together, and it seems to work well and safely.
Methodology
This retrospective study included 22 patients with 23 lesions treated with SpECT, focusing on safety, efficacy, and outcomes.
Potential Biases
The findings may not be generalizable due to the specific patient population and treatment protocols used.
Limitations
The study is limited by its single-center design, small sample size, and lack of a control group.
Participant Demographics
The mean patient age was 63 years, with 77.3% male and 22.7% female participants.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website